Caplin Steriles gets USFDA approval for Levetiracetam in Sodium Chloride Injection Infusion bags
Drug Approval

Caplin Steriles gets USFDA approval for Levetiracetam in Sodium Chloride Injection Infusion bags

This is the second Ready-To-Use Infusion bag (RTU Bags) ANDA drug product approved for Caplin Steriles

  • By IPP Bureau | January 18, 2025

Caplin Steriles Limited, a subsidiary company of Caplin Point Laboratories Limited, has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Levetiracetam in Sodium Chloride Injection, 500mg/100mL, 1000mg/100mL and 1500mg/100mL Infusion bags (Large Volume Parenteral), a generic therapeutic equivalent version of the Reference Listed Drug (RLD), from HQ Speciality Pharma Corp.

This is the second Ready-To-Use Infusion bag (RTU Bags) ANDA drug product approved for Caplin Steriles, with a further six products under review with FDA for RTU Bags segment.

Levetiracetam in Sodium Chloride Injection is an antiepileptic drug indicated for adjunctive therapy, in the treatment of partial-onset seizures in adults with epilepsy and in the treatment of myoclonic seizures in adults with juvenile myoclonic epilepsy and iii) in the treatment of primary generalized tonic-clonic seizures in adults with idiopathic generalized epilepsy.

According to IQVIA (IMS Health), Levetiracetam in Sodium Chloride Injection had US sales of approximately US $19 million for the 12-month period ending November 2024.

Upcoming E-conference

Other Related stories

Startup

Digitization